author-photo

Ellis J. Neufeld

Boston Children's Hospital
St. Jude Children's Research Hospital

142

Papers

2645

Citations

Citation Trend

Filter By

Papers (93) Sort By

Journal Conference Others

Reduced Dosing Frequency Following a Switch to Rix-FP for the Treatment of Hemophilia B: Results from the Athn 2 Study

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Comorbidities and complications in adults with pyruvate kinase deficiency.

2021 European Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (1)
Phase 3 randomised trial of eltrombopag versus standard first-line pharmacological management for newly diagnosed immune thrombocytopaenia (ITP) in children: study protocol.

2021 BMJ Open
Show All
- Source
- Cite
- Save
Citations (0)
Limited sampling strategies for accurate determination of extended half-life factor VIII pharmacokinetics in severe haemophilia A patients.

2021 Haemophilia
Show All
- Source
- Cite
- Save
Citations (0)
Dosing, Patient Satisfaction and Other Patient-Reported Outcomes after Switching to Rurioctocog Alfa Pegol in Athn 2: A Longitudinal, Observational Study of Previously Treated Hemophilia Patients Switching Coagulation Replacement Factor Products

2020 Blood
Show All
- Source
- Cite
- Save
Citations (0)
A Phase 3 Study of Eltrombopag Vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia in Children

2019 Blood
Show All
- Source
- Cite
- Save
Citations (1)
Regional variation and cost implications of prescribed extended half‐life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia

2019 Haemophilia
Show All
- Source
- Cite
- Save
Citations (20)
Comorbidities and Complications in Adults with Pyruvate Kinase Deficiency

2019 Blood
Show All
- Source
- Cite
- Save
Citations (1)
Lack of Inhibitor Development in the American Thrombosis and Hemostasis Network (ATHN)-2 Factor Switching Study: Preliminary Report of Primary Outcome

2019 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States

2018 Journal of Medical Economics
Show All
- Source
- Cite
- Save
Citations (8)